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O B J E C T I V E :  To explore the consequences of translating 
the International Study of Asthma and Allergies in Child-
hood (ISAAC) English core questionnaires on asthma, 
rhinitis and eczema symptoms into other languages.
D E S I G N :  ISAAC Phase III developed 49 language trans-
lations for adolescents and 42 for children following stan-
dardised guidelines, which included back-translating the 
questionnaires into English to check their accuracy and 
meaning. Language deviations were categorised and an-
alysed with regard to infl uences on the reported symp-
tom prevalence.
R E S U LT S :  Category 1 deviations for one or more ques-
tions were found in seven translations (14%) for adoles-
cents and in three translations (7%) for children. Data 
for these questions were excluded from the worldwide 
analyses. Category 2 deviations were identifi ed in the 
publications, and Category 3 deviations were ignored.
C O N C L U S I O N S :  Translations of questionnaires should 
follow a consistent protocol in global epidemiological 
research. Cultural norms need to be considered when 
evaluating back-translations into English, as disease la-
bels are not available in every language, nor are they un-
derstood in the same way. Deviations from literal trans-
lations of English should be permitted if the intent of the 
original meaning is retained. A web-based tool of medi-
cal terminology would be useful for international re-
search requiring the use of translations.
K E Y  W O R D S :  ISAAC; children; translation; epidemiol-
ogy; asthma; rhinitis; eczema
ALTHOUGH QUESTIONNAIRE TOOLS are used 
widely in epidemiological research, little has been 
written about possible loss of validity during transla-
tion when used in comparative international studies. 
The process of questionnaire translation and back-
translation is seldom, if at all, described. Here, we re-
port the processes and consequences of translating 
questionnaires used in a major global epidemiologi-
cal survey of allergic diseases.
The International Study of Asthma and Allergies in 
Childhood (ISAAC), the largest epidemiological study 
in children,1 was designed in 1991 to describe the 
world-wide symptom prevalence of asthma, rhinitis 
and eczema in schoolchildren. Validated questions were 
used, where possible, and questionnaires were designed 
in English by the ISAAC Steering Committee mem-
bers, representing 12 countries and 10 languages.2
ISAAC Phase III (2001–2005), a repeat of Phase I 
(1991–1996), was cross-sectional, school-based and 
S U M M A R Y
# See Acknowledgements.
involved adolescents aged 13–14 years and children 
aged 6–7 years. Standardised core written question-
naires,2 translated into local languages following de-
tailed guidelines, were self-completed by adolescents 
and by parents of the children.3,4 A video question-
naire depicting symptoms of asthma, not dependent 
upon written languages, was developed for optional 
use for the adolescents.5
ISAAC Phase III involved 233 centres from 97 coun-
tries for adolescents and 144 centres from 61 coun-
tries for children. Comparability and replication of 
methodology are important aspects of repeated cross-
sectional surveys,6 including question validity and the 
use of translations. Questionnaire translation and 
back-translation into English by an independent per-
son was considered a key issue for data comparison. 
Translating an instrument into another language can 
be subject to cultural and linguistic variations and the 
most crucial step in the adoption of a well-developed 
instrument in another language.7 In ISAAC Phase III, 
questionnaire translations used in various cultural 
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contexts allowed us to analyse possible consequences 
for data analysis and interpretation of outcomes.
METHOD
ISAAC translation process
Translated questionnaires were required to have the 
same structure and logic as the original. As it was im-
portant for the questions to be correctly understood 
by the participants, translations needed to apply the 
language used by the children and parents themselves, 
rather than the terminology of medical professionals. 
Previous experience from an ISAAC Phase I pilot 
study in Germany had shown that this could be a 
problem.4 Guidelines were written to ensure a consis-
tent protocol,3 and are summarised in Table 1. It be-
came apparent before starting Phase III that evalua-
tion of the back-translations into English was an 
important quality control process, due to concerns 
about possible incorrect translations in Phase I.
Data centre processes
The Phase III Manual3 included language codes that 
collaborators precoded onto questionnaires to iden-
tify the languages used (e.g., 001 = Afrikaans, 002 = 
Albanian, etc.). Centres completed a Centre Report, 
which was submitted to the ISAAC International Data 
Centre (IIDC) at the time of data submission. The 
Centre Report asked detailed questions about aspects 
of the study methodology,3 including the translation 
process: whether the translator/s were familiar with 
asthma, rhinitis and eczema terminology; the consulta-
tion process with local communities; the process under-
taken to develop translations and back-translations; 
and if the translations were pilot tested. 
Ethics committee approval was a requirement for 
the ISAAC fi eldwork, but was not necessary for this 
evaluation of the back-translations into English. The 
Centre Report documented the date ethics approval 
was obtained and the name of the ethics committee 
that approved the study.
Analysis of translations
At the beginning of Phase III, a sub-committee of 
the ISAAC Steering Committee reviewed the back-
translations to observe how closely the original En-
glish version was followed (those not received were 
back-translated by a professional translation service 
following the same IIDC procedure). Identifying in-
formation about the centre and language was re-
moved for anonymity to ensure impartial judgment. 
Deviations from the original English version were as-
sessed in three categories: Category 1 for major devi-
ations that were considered severe enough to change 
the meaning of the question; Category 2 for minor de-
viations where extra questions had been inserted or 
where there had been partial exclusion of data; and 
Category 3 for very minor deviations that did not 
alter the meaning of the question. Empirical defi nitions 
derived by the Translation Subcommittee of what con-
stituted Category 1, 2 and 3 violations are elaborated 
in Table 2. The Translation Subcommittee, aware there 
Table 1 Guidelines for the translation of the ISAAC English 
language questionnaire
1 The English language questionnaire should be translated by 
people who are bilingual and familiar with the area in which the 
questionnaire would be used
2 To ﬁ nd the most appropriate translation for difﬁ cult terms, 
investigators were encouraged to i) ask local doctors about local 
words to describe these terms; ii) ask children with these 
conditions and parents of children with these conditions how 
they would describe the conditions; iii) show the ISAAC video 
and ask children with asthma and parents of children with 
asthma how they would describe the breathing of the 
participants in the video; iv) submit a list of possible descriptors 
to children with asthma, rhinitis and eczema and parents of 
children with these conditions and ask them to indicate, 
e.g., using a rating system, which description(s) they favour
3 The most appropriate translation should be agreed upon among 
a group of national experts on the basis of 2 (i–iv). National 
questionnaires should allow for differences in the wording of 
questions according to the local use of language
4 The questionnaires should be translated back into English by an 
independent translator and modiﬁ cations made if necessary
5 The questionnaires should be tested in populations that are 
representative of the study population. Modiﬁ cations should be 
made if necessary
Steps 2 to 5 are repeated if required.
ISAAC = International Study of Asthma and Allergies in Childhood.
Table 2 Codes assigned to the questions from the 
back-translations into English
Code Action taken
Category 1 Major deviations from 
the original English language 
question, severe enough to change 
the meaning of the question 
entirely or partly, with possible 
consequence on the outcome. For 
example: ‘Have you ever had 
hayfever?’ translated to ‘Have you 
ever had a post nasal growth?’ and 
‘Have you ever had eczema?’ trans-
lated to ‘Have you ever been sick 
with a skin condition called vitiligo?’
Exclude the data for the 
question from the 
analyses and publi-
cations and identify the 
centre’s lack of data in 
the publications with a 
footnote
Category 2 Minor deviations, such 
as the use of a dual language 
questionnaire; additional questions 
administered before or in between 
the core ISAAC questions; partial 
exclusion of data; questions not 
administered in the correct order; 
a different translation used in 
Phase I from that in Phase III
Include the question in the 
analyses and identify 
the centre in the ﬁ rst 
worldwide publications 
with a footnote to alert 
the reader to the fact 
that it was not known 
what effect these devi-
ations could have on 
the outcome data
Category 3 Very minor deviations. 
For example: changes to the English 
language questionnaire which did 
not appear to change the meaning 
of the question; some terminology 
not exact but was correct for the 
culture; and errors found in the back- 
translation. For example: ‘Have you 
ever had asthma?’ translated to 
‘Have you ever had asthma or 
asthmatiform bronchitis?’
Include the question in the 
analyses without 
identiﬁ cation
ISAAC = International Study of Asthma and Allergies in Childhood.
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was not a translation in every language for some clini-
cal descriptions and disease terminology, gave careful 
consideration to these questions to avoid unnecessary 
exclusion of questions. For example, in some languages 
‘wheeze’ did not have an obvious synonym, while ‘rhi-
nitis’, ‘hayfever’ and ‘eczema’ were identifi ed as anglo-
centric words that could be diffi cult to translate.
The Translation Subcommittee consulted with local 
investigators and National/Regional Coordinators re-
garding these deviations and made the following de-
cisions. For Category 1 deviations, they decided to: 
1) distinguish between the clearly wrong and the un-
sure deviations; 2) make a fi nal list of the serious devi-
ations; 3) request a second back-translation to confi rm 
that the deviation was in fact true; and 4) consider 
excluding the data for the question from publica-
tions. For the Category 2 translations, as it was not 
possible to identify whether the analyses would be af-
fected, the deviations were identifi ed by the use of a 
footnote in the worldwide publications to alert the 
reader to the fact that minor adjustments had been 
made to the translation. For the Category 3, very mi-
nor deviations, these were considered too minor to 
have any effect and were subsequently ignored.
A sensitivity analysis was then undertaken to ex-
amine how the regional prevalence values changed 
when the mistranslated data were included.
RESULTS
Adolescent group
A total of 233 centres from 97 countries participated in 
the ISAAC Phase III study. The questionnaire was trans-
lated into 49 languages and used in 201 centres. One 
language only was used in 190 centres (94%), 10 (5%) 
centres used two languages, and one centre used three 
(0.4%) languages. Table 3 shows the languages and the 
number of centres that used each translation. Spanish 
(48 centres, 21%) was the language most commonly 
used. English was used exclusively in 32 centres (14%), 
and in another 15 centres as a proportion, with other 
languages making up the remainder (for example, 
one centre used English for 32% and Urdu [68%] for 
the rest). Other languages were Portuguese (25 cen-
tres, 11%), Arabic (16 centres, 7%), Italian (13 cen-
tres, 6%), French (11 centres, 5%), Chinese and Hindi 
(both 8 centres, 3%) and Ma rathi (7 centres, 3%). The 
other 41 languages made up the remainder. To accom-
modate local variations in dialect, some countries de-
veloped several questionnaires, notably in Spanish.
Of the 49 translations archived at the IIDC, 30 
(61%) back-translations to English were received at 
the IIDC from Regional Coordinators. The remain-
ing 19 translations were undertaken by the profes-
sional translation service (Figure 1).
Category 1 deviations 
One centre was excluded entirely due to an inappro-
priate translation (and for other protocol deviations). 
In six centres, translation deviations were found that 
were considered severe enough to exclude the data for 
one or more questions from the data analyses. These 
centres were identifi ed by a footnote in the ISAAC 
worldwide publications.8,9
Category 2 deviations
Twenty-four centres had translation deviations in one 
or more questions that required a footnote in the 
Table 3 Languages used in ISAAC Phase III for the 13–14 year 
age group; number of centres for each language shown 
in parentheses
Afrikaans (2)
Albanian (1)
Amharic (1)
Arabic (16)
Basque (1)
Bulgarian (1)
Chinese (8)
Croatian (1) 
Dutch (2)
English (47)
Estonian (1)
Finnish (1)
French (11)
Georgian (1)
German (2) 
Hindi (8)
Hungarian (3)
Indonesian (3)
Italian (13)
Japanese (2)
Kannada (1)
Korean (2) 
Kyrgyz (3)
Latvian (1)
Lithuanian (3)
Macedonian (1)
Malay (3)
Maltese (1)
Malyalam (1)
Marathi (7)
North Sotho (1)
Persian (4)
Polish (2)
Portuguese (25)
Romanian (1)
Russian (7)
Samoan (1)
Serbian (5)
Sinhala (1)
Spanish (48)
Swedish (1)
Tagalog (1)
Tamil (2) 
Thai (6)
Tokelau (1)
Tongan (1)
Urdu (2)
Uzbek (1)
Vietnamese (1)
Xhosa (1)
ISAAC = International Study of Asthma and Allergies in Childhood.
Figure 1 Flow chart depicting number of languages and devi-
ations in the 13–14 year age group (adolescents).
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worldwide publications:8,9 one centre used a dual lan-
guage questionnaire, 17 centres included their own 
questions within the core ISAAC questionnaire, and 
two centres had partial data excluded from the data 
analyses; one of these centres used ‘hayfever ever’ and 
then switched to ‘rhinitis ever’, resulting in the exclu-
sion of ‘rhinitis ever’ from the analyses. The other 
centre had ‘hayfever ever’ excluded for one language 
(North Sotho) due to an inappropriate translation; 
however, the other languages used (English 30% and 
Afrikaans 10%) for this question were appropriate; 
three centres did not administer the questions in the 
correct order; and one centre used a different transla-
tion for Phase III from that of Phase I.8
Category 3 deviations
Category 3 deviations were found in 12 centres; how-
ever, these were considered minor enough not to affect 
the results and were not identifi ed in the publications.
Children
A total of 144 centres (61 countries) participated in 
ISAAC Phase III. The questionnaire was translated 
into 42 languages and used in 131 centres. One lan-
guage only was used in 120 centres (83%). Nine cen-
tres (6%) used two languages, one centre (0.7%) used 
three languages and one centre (0.7%) used four lan-
guages. Table 4 shows the languages and the number 
of centres that used each translation. Spanish (36 cen-
tres, 21%) was the language most commonly used, 
followed by English (26 centres, 20%), Portuguese 
(13 centres, 11%) and Italian (10 centres, 6%). The 
other 38 languages made up the remainder.
Of the 42 translations archived at the IIDC, 22 
(52%) back-translations to English were received by 
the IIDC. The remaining 20 translations were under-
taken by the professional translation service (Figure 2).
Category 1 deviations
One centre was excluded entirely due to an inappro-
priate translation (and due to other protocol devia-
tions); two centres had translation deviations which 
were considered severe enough to exclude the data 
for one or more questions. These centres were identi-
fi ed in the worldwide publications by a footnote.8,9
Category 2 deviations 
Thirteen centres had translation deviations in one or 
more questions that required a footnote in the world-
wide publications;8,9 one centre used a dual language 
questionnaire; eight centres included their own ques-
tions within the core ISAAC questionnaire; one centre 
had ‘hayfever ever’ excluded for one language (North 
Sotho) due to an inappropriate translation, however 
the other two languages used for this question (En-
glish 10% and Afrikaans 5%) were appropriate. Two 
centres did not administer the questions in the cor-
rect order and one centre used a different translation 
for Phase III to that of Phase I.8
Category 3 deviations 
Category 3 deviations were found in nine centres; how-
ever, they were considered minor enough not to affect 
the results and were not identifi ed in the publications.
Both age groups, sensitivity analysis
Inclusion of the mis-translated questions increased or 
reduced symptom prevalence values by 0.5% or more 
Table 4 Languages used in ISAAC Phase III for the 6–7 year 
age group; number of centres for each language shown 
in parentheses
Afrikaans (1)
Albanian (1)
Arabic (7)
Basque (1)
Bulgarian (1)
Catalan (1)
Chinese (5)
Croatian (1)
Dutch (1)
English (26)
Estonian (1)
Georgian (1)
German (3) 
Greek (1)
Hebrew (1)
Hindi (5)
Hungarian (2)
Indonesian (1)
Italian (10)
Japanese (1)
Kannada (1)
Korean (2)
Kyrgyz (2)
Lithuanian (3)
Malay (4)
Maltese (1)
Malayalam (1)
Marathi (7)
North Sotho (1)
Persian (4)
Polish (2)
Portuguese (13)
Russian (5)
Serbian(4)
Sinhala (1)
Spanish (36)
Swedish (1)
Tamil (1)
Thai (6)
Turkish (1)
Urdu (2)
Uzbek(1)
Vietnamese (1)
Figure 2 Flow chart depicting number of languages and devi-
ations in the 6–7 year age group (children).
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in four variables for the adolescents and two for the 
children. For example, for Asia Pacifi c, ‘eczema ever’ 
increased by 1.4% for the adolescents and by 2.2% 
for the children (Appendix Tables 1 and 2).*
DISCUSSION
Main ﬁ ndings
Precision in translating questions from English to 
other languages was a challenging methodological is-
sue, despite the availability of detailed guidelines to 
ensure consistent methodology. This was not antici-
pated when ISAAC was designed in 1990/1991, as 
few large studies using multiple translations had been 
undertaken and little had been written about the sub-
ject. Whilst the ISAAC Steering Committee acknowl-
edged that some clinical terminology would be diffi -
cult to translate, such as asthma, rhinitis and eczema, 
we believed these words would be accurately ex-
plained in other languages by a local person familiar 
with the terminology and that local investigators or 
National/Regional Coordinators were the appropriate 
people to undertake the translation process rather than 
a centralised independent translating service. This was 
not always the case, however. The video questionnaire 
showing visual scenes of various asthma symptoms 
arose from the uncertainty of translating the written 
English language questionnaires into other languages. 
The ISAAC written questionnaires have a reasonable 
correlation with the video questionnaire,5,10 and others 
have undertaken their own validation of the ISAAC 
questionnaire.11–21
Of interest was the sensitivity analysis, with the ad-
olescent group showing more increases in prevalence 
values for the excluded questions than children. This 
may refl ect the possibility that the parents of the chil-
dren were able to understand the mistranslated ques-
tions more easily than the adolescents, and it would 
have been useful to address this issue more fully.
Consequences of translation errors
Although translation errors cannot be ignored, only a 
few were major, requiring data exclusion. These deci-
sions were made after independent back-translation 
into English was undertaken to confi rm that the ques-
tion/s were in fact inaccurate and after discussion with 
the Principal Investigator or National/Regional Co-
ordinators. The rigorous process undertaken to con-
fi rm that other deviations found were true translation 
deviations resulted in few footnotes. The rechecking, 
done by the independent translation service, and the 
ensuing dialogue with collaborators, seeking their 
local knowledge, resulted in the appropriate clarifi ca-
tion and resolution of most of the issues.
Comparisons with other international studies
Similar approaches using standardised protocols for 
translations and back-translations into English were 
undertaken in two other large international cross-
sectional multi-centre studies, the European Commu-
nity Respiratory Health Survey (ECRHS)22 and the 
Multinational MONItoring of trends and determi-
nants in CArdiovascular disease (MONICA).23 These 
studies reported that they included quality assurance 
and studied internal validity; however, ISAAC has taken 
a more comprehensive and rigorous approach to the 
back-translation issue, as described in this paper, as 
well as making suggestions for a more robust approach 
to the process of translating the English language ques-
tionnaire into other languages. Other, smaller studies 
have also identifi ed the importance of appropriate 
questionnaire translation7,24–28 to allow confi dence in 
the accuracy of the data collected.
Some English words are difﬁ cult to translate
Some terminology was diffi cult to translate into other 
languages despite a detailed protocol. The English 
word ‘wheeze’ is an obvious example, as an exact syn-
onym was lacking in most other languages. This prob-
lem was solved by suggesting various words and com-
binations of words to a panel of asthmatic children 
and their parents.4 The word ‘hayfever’ is not mean-
ingful in countries with no distinct pollen seasons 
and, as succinctly put by one collaborator, is not re-
lated to either ‘hay’ or ‘fever’. Likewise, ‘itchy rash’ 
and ‘eczema’ have their own interpretation problems 
in some languages.
Implications for future research
Translation processes are a vital component of meth-
odology and should be validated internally and ex-
ternally to guarantee confi dence in the data. Ideally, 
translations and back-translations into English should 
be carefully compared by coordinating centres before 
studies commence. This allows comparisons to be 
made of languages used for diffi cult terminology and 
a new translation developed if required, thus avoid-
ing later diffi culties. A web-designed database of ter-
minology would be useful when planning large-scale 
research projects. This could include technical terms 
such as those found in the ISAAC questionnaire, and 
include typical medical nouns such as ‘asthma’, ‘hay-
fever’ and ‘eczema’, along with defi nitions in English 
and their typical translation into other languages. De-
scriptive terms should be included, such as ‘wheezing’ 
and ‘whistling’ and other terms related to the three 
conditions used in the ISAAC study. A database such 
as this could be useful for other large international 
epidemiological studies and smaller studies where a 
translated questionnaire is used, as well as being a use-
ful addition to the ISAAC tools currently available.†* Available in the online version of this article at http://www.ingenta 
connect.com/content/iuatld/ijtld/2009/00000013/00000009/
art00021 † http://isaac.auckland.ac.nz
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Despite our initial misgivings when beginning 
ISAAC Phase III, we found that repeated cross-
s ectional epidemiological multicentre studies through-
out the world, such as ISAAC, are feasible and achiev-
able, using multiple language translations by people 
with diverse cultural backgrounds. With careful doc-
umentation and communication, errors can be mini-
mised to allow international comparisons of data to 
be undertaken. Allowances must be made for differ-
ences in terminology where cultural backgrounds are 
diverse and where cultures within countries are 
changing. These studies set the foundation to improve 
child and adolescent health outcomes worldwide.
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R Goulding (Jersey); Chile: LAV Benavides (Calama), A 
Contreras (Chiloe), L Amarales (Punta Arenas), P Aguilar 
(South Santiago), MA Calvo (Valdivia); China: YZ Chen† 
(Beijing, Tong Zhou), N-S Zhong (Guangzhou), O Kunii 
(Tibet), Q Li Pan (Wulumuqi); Colombia: AM Cepeda† 
(Barranquilla), G Aristizábal (Bogotá), GA Ordoñez (Cali); 
Congo: J M’Boussa (Brazzaville); Cook Islands: R Daniel† 
(Rarotonga); Costa Rica: ME Soto-Quirós†; Cote d’Ivoire: 
BN Koffi † (Urban Cote d’Ivoire); Croatia: KL Tomulic 
(Rijeka); Cuba: P Varona Peréz† (La Habana); Ecuador: 
* Regional Coordinator
† National Coordinator
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C Bustos (Guayaquil), S Barba† (Quito); Egypt: ML Na-
guib (Cairo); El Salvador: M Figuero Colorado† (San Sal-
vador); Estonia: M-A Riikjärv† (Tallinn); Ethiopia: K 
Melaku (Addis Ababa); Fiji: R Sa’aga-Banuve (Suva); Fin-
land: J Pekkanen† (Kuopio County); Former Yugoslav Re-
public of Macedonia (FYROM): E Vlaski† (Skopje); Gabon: 
IE Hypolite† (Port-Gentil); Georgia: M Gotua† (Kutaisi); 
Germany: U Keil† (Münster); Greece: J Tsanakas (Thessa-
loniki); Honduras: A Bueso-Engelhardt† (San Pedro Sula); 
Hong Kong: G Wong (Hong Kong, 13–14 years), YL Lau 
(Hong Kong, 6–7 years); Hungary: G Zsigmond† (Svábhe-
gy), Z Novák (Szeged); India: S Rego (Bangalore), M Sabir 
(Bikaner), VA Khatav (Borivali), L Kumar (Chandigarh), G 
Setty (Chennai [3]‡), PS Babu (Davangere), V Singh (Jaipur), 
KC Jain (Jodhpur), TU Sukumaran (Kottayam), S Awasthi 
(Lucknow), J Chhatwal (Ludhiana), MK Joshi (Mumbai 
[16]), AV Pherwani (Mumbai [18]), SN Mantri (Mumbai 
[29]), S Salvi (Nagpur, Pimpri), SK Sharma (New Delhi [7]), 
NM Hanumante (Pune), S Bhave (Rasta Peth); Indonesia: P 
Konthen (Bali), CB Kartasasmita (Bandung), W Suprihati 
(Semarang); Iran: M-R Masjedi† (Birjand, Rasht, Tehran, 
Zanjan); Isle of Man: A Steriu; Italy: L Armenio (Bari), V 
Dell’Orco (Colleferro-Tivoli), E Bonci (Cosenza), C Galassi 
(Emilia-Romagna), MG Petronio (Empoli), E Chellini (Fi-
renze), G Giannella (Mantova), L Bisanti (Milano), S La 
Grutta (Palermo), F Forastiere† (Roma), P Sestini (Siena), G 
Ciccone (Torino), S Piffer (Trento), Japan: H Odajima (Fu-
kuoka), M Sohei (Tochigi); Jordan: F Abu-Ekteish (Am-
man); Kenya: FO Esamai (Eldoret), L Ng’ang’a† (Nairobi); 
Kingdom of Tonga: S Foliaki (Nuku’alofa); Kuwait: JA al-
Momen; Kyrgyzstan: C Imanalieva† (Balykchi, Bishkek), S 
Sulaimanov (Jalalabat); Latvia: V Svabe (Riga); Lithuania: 
J Kudzyte† (Kaunas), J Bojarskas (Panevezys, Siauliai); Ma-
laysia: KH Teh (Alor Setar), J de Bruyne† (Klang Valley), 
BS Quah (Kota Bharu); Malta: S Montefort†; Mexico: BE 
Del-Río-Navarro (Ciudad de México [1]), M Barragán-
Meijueiro (Ciudad de México [3]), N Ramírez-Chanona 
(Ciudad de México [4]), R García-Almaraz (Ciudad Victo-
ria), I Romieu (Cuerna vaca), M Baeza-Bacab† (Mérida), JV 
Merida-Palacio (Mexicali Valley), SN González-Díaz (Mon-
terrey), FJ Linares-Zapién (Toluca), S Romero-Tapia (Villa-
hermosa); Morocco: Z Bouayad† (Benslimane, Boulmene, 
Casablanca, Marrakech); The Netherlands: R Engels; New 
Zealand: MI Asher† (Auckland), C Moyes (Bay of Plenty), 
P Pattemore (Christchurch), R MacKay (Nelson), N Pearce 
(Wellington); Nicaragua: JF Sánchez† (Managua); Nigeria: 
BO Onadeko (Ibadan); Niue: M Magatogia (Niue Island); 
Nouvelle Caledonie: I Annesi-Maesano; Pakistan: MO Yu-
suf (Islamabad), N Mahmood† (Karachi); Palestine: S Mor-
taja (North Gaza), N El Sharif† (Ramallah); Panama: G 
Cukier† (David-Panamá); Paraguay: JA Guggiari-Chase† 
(Asunción); Peru: P Chiarella† (Lima); Philippines: F Cua-
Lim† (Metro Manila); Poland: G Lis† (Kraków), A Brêboro-
wicz (Poznan); Polynesie Francaise: I Annesi-Maesano; 
Portugal: ML Chiera (Coimbra), R Câmara (Funchal), JE 
Rosado Pinto† (Lisbon), C Nunes (Portimao), JM Lopes 
dos Santos (Porto); Republic of Ireland: L Clancy; Répub-
lique de Guinée: OY Sow (Conakry); Republique Democra-
tique du Congo: J-M Kayembe (Kinshasa); Reunion Island: 
I Annesi-Maesano†; Romania: D Deleanu (Cluj); Russia: 
EG Kondiourina (Novosibirsk); Samoa: P Fuimaono 
(Apia); Serbia and Montenegro: Z Zivkovic† (Belgrade), S 
Zivanovic (Nis), M Hadnadjev (Novi Sad), O Adzovic 
(Podgorica), E Panic (Sombor); Singapore: DYT Goh; 
South Africa: HJ Zar† (Cape Town), K Voyi (Polokwane); 
South Korea: H-B Lee† (Provincial Korea, Seoul); Spain: A 
López-Silvarrey Varela (A Coruña), JB Garrido (Almeria), I 
Carvajal-Urueña (Asturias), RM Busquets (Barcelona), CG 
Díaz (Bilbao), L García-Marcos† (Cartagena), A Arnedo-
Pena (Castellón), G Garcia-Hernández (Madrid), F Guillén-
Grima (Pamplona), EG Pérez-Yarza (San Sebastián), MM 
Morales Suárez-Varela (Valencia), A Blanco Quirós (Valla-
dolid); Sri Lanka: KD Gunasekera†; Sudan: OAA Muza 
(Khartoum); Sul tanate of Oman: O Al-Rawas† (Al-Khod); 
Sweden: H Vogt (Linköping); Syrian Arab Republic: K Tab-
bah (Aleppo), Y Mohammad (Lattakia), S Mohammad† 
(Tartous); Taiwan: J-L Huang† (Taipei), C-C Kao (Tao-
yuan); Thailand: P Vichyanond† (Bangkok), T Prasarn-
phanich (Chantaburi), M Trakultivakorn (Chiang Mai), R 
Nettagul (Chiangrai), J Teeratakulpisarn (Khon Kaen), A 
Kongpanichkul (Nakorn Pathom); Togo: O Tidjani (Lome); 
Tokelau: T Iosefa†; Trinidad and Tobago: MA Monteil (St 
Augustine, Tobago); Tunisia: F Khaldi (Grand Tunis), M 
Jerray (Sousse); Ukraine: V Ognev† (Kharkiv, Rural Khar-
kiv); United Kingdom: HR Anderson† (North Thames, 
South Thames), JB Austin (Scotland), MH Shamssain (Sun-
derland), D Strachan (Surrey/Sussex), M Burr (Wales); Uru-
guay: D Holgado† (Montevideo), MC Lapides (Paysandú); 
United States: K Yeatts (Chapel Hill), HH Windom (Sara-
sota), GJ Redding (Seattle); Venezuela: O Aldrey† (Cara-
cas); Vietnam: B Vaên Cam (Ho Chi Minh City).
ISAAC Phase III National Coordinators not identiﬁ ed above
Canada: M Sears; Channel Islands: HR Anderson; Chile: V 
Aguirre; Croatia: V Ahel; Greece: C Grat ziou; Hong Kong: 
CKW Lai; India: J Shah; Indonesia: K Baratawidjaja; Isle of 
Man: HR Anderson; Japan: S Nishima; Kingdom of Tonga: 
T Fakakovi; The Netherlands: R Otten; Nouvelle Caledo-
nie: S Barny; Polynesie Francaise: R Chansin; Republic of 
Ireland: P Man ning; Republique Democratique du Congo: 
E Bahati; Russia: RM Khaitov; Samoa: N Tuuau-Potai; Sin-
gapore: B-W Lee; Sudan: A El Sony; Sweden: L Nilsson.
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R É S U M É
O B J E C T I F  :   Explorer les conséquences de la traduction 
en d’autres langues des questionnaires anglais de base 
de l’International Study of Asthma and Allergies in 
Childhood (ISAAC) au sujet de l’asthme, de la rhinite et 
des symptômes d’eczéma. 
S C H É M A  :   Au cours de la Phase III de l’ISAAC, on a 
élaboré 49 traductions pour adolescents et 42 pour en-
fants en respectant les directives standardisées qui com-
portaient la rétro-traduction en anglais du questionnaire 
afi n de contrôler sa précision et sa signifi cation. Les dé-
viations de langage ont été catégorisées et analysées en 
ce qui concerne leur infl uence sur la prévalence signalée 
des symptômes.
R É S U LTAT S  :   On a observé des déviations de Catégorie 
1 pour une ou plusieurs questions dans sept traductions 
(14%) pour les adolescents et dans trois traductions 
(7%) pour les enfants. On a exclu pour ces questions les 
données des analyses au niveau mondial. Des déviations 
de Catégorie 2 ont été identifi ées dans les publications et 
on a ignoré les déviations de Catégorie 3.
C O N C L U S I O N S  :   Dans les recherches épidémiologiques 
mondiales, les traductions de questionnaires doivent re-
specter un protocole cohérent. Il y a lieu de prendre en 
considération les normes culturelles lorsqu’on évalue 
les rétro-traductions vers l’anglais, car les dénomina-
tions des maladies ne sont pas disponibles dans toutes 
les langues ni comprises de la même manière. Des dévia-
tions provenant des traductions littérales à partir de 
l’anglais doivent être permises lorsque l’intention de la 
signifi cation originale est maintenue. Un outil en ligne 
concernant la terminologie médicale pourrait être utile 
pour les recherches internationales nécessitant l’utilisation 
de traductions.
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R E S U M E N
O B J E T I V O  :   Examinar las consecuencias de la traducción 
a otros idiomas de los cuestionarios básicos en inglés del 
Estudio Internacional de Asma y Alergias en la Niñez 
(ISAAC) sobre los síntomas de asma, rinitis y eczema. 
M É T O D O S  :   En la Fase III del ISAAC se realizaron 49 
traducciones de cuestionarios destinados a los adoles-
centes y 42 a los niños, siguiendo recomendaciones nor-
malizadas que comprendían la retrotraducción de las 
preguntas al inglés, con el fi n de verifi car la exactitud y 
el sentido. Las desviaciones del idioma se clasifi caron y 
analizaron en función de su infl uencia sobre la prevalen-
cia comunicada de los síntomas.
R E S U LTA D O S  :   Se observaron desviaciones de primera 
categoría en una o más preguntas de siete traducciones 
dirigidas a los adolescentes (14%) y en tres traducciones 
dirigidas a los niños (7%). Los datos sobre estas pre-
guntas se excluyeron del análisis mundial. Se detec-
taron desviaciones de segunda categoría en las publica-
ciones y no se tuvieron en cuenta las desviaciones de 
tercera categoría.
C O N C L U S I Ó N  :   En la investigación epidemiológica 
mundial, las traducciones de los cuestionarios deben 
seguir un protocolo homogéneo. Es preciso tener en 
cuenta las normas culturales cuando se evalúa la retro-
traducción al inglés, pues no todas las enfermedades 
cuentan con términos equivalentes en cada idioma, ni se 
comprenden de la misma manera. Se deben permitir las 
desviaciones de la traducción literal del inglés, siempre y 
cuando se conserve la intención del signifi cado original. 
Sería de gran utilidad contar con una herramienta de 
terminología médica en línea para toda investigación 
internacional en la cual se recurre a las traducciones.
APPENDIX TABLE 1 
Effect of inclusion of mistranslated questions, ISAAC Phase Three, 13–14 year age group 
 Asia-Pacific Oceania Indian Sub-continent 
 Without 
mistranslations 
% 
With 
mistranslations 
% 
 
Difference 
% 
Without 
mistranslations 
% 
With 
mistranslations 
% 
 
Difference 
% 
Without 
mistranslations 
% 
With 
mistranslations 
% 
Difference 
% 
No interference with 
activities in last  
12 months 
   
13.0 12.8 –0.2 
   
A little interference 
with activities in 
last 12 months 
   
 
20.8 
 
20.0 
 
–0.7 
   
Moderate 
interference with 
activities in last  
12 months 
   
 
3.6 
 
4.2 
 
0.5 
   
A lot of interference 
with activities in 
last 12 months 
   
 
2.0 
 
2.5 
 
0.4 
   
Hayfever ever    24.4 21.8 –2.6 18.5 18.4 –0.1 
Rash ever 8.6 9.0 0.4    7.3 7.4 0.1 
Current rash 7.2 7.7 0.4       
Rash in flexures 6.2 6.4 0.3       
Rash cleared in    
last 12 months 5.8 6.1 0.3 
      
Sleep disturbance 
from rash never 12.3 12.2 –0.1 
      
Sleep disturbance 
from rash <1 night 
per week 2.7 2.7 0.0 
      
Sleep disturbance 
from rash >1 night 
per week 1.0 1.0 0.0 
      
Eczema ever 14.4 15.7 1.4       
Current eczema 
symptoms 5.3 5.6 0.3 
      
 
APPENDIX TABLE 2 
Effect of inclusion of mistranslated questions, ISAAC Phase Three, 6–7 year age group 
 Asia-Pacific Indian Sub-continent 
 Without 
mistranslations 
% 
With 
mistranslations 
% 
 
Difference 
% 
Without 
mistranslations 
% 
With 
mistranslations 
% 
 
Difference 
% 
Hayfever ever    9.0 9.1 0.1 
Rash ever 13.4 13.8 0.4 5.5 5.4 –0.1 
Current rash 12.8 13.2 0.4    
Rash in flexures 11.7 12.0 0.3    
Rash at <2 years 5.0 5.3 0.3    
Rash at 2–4 years 4.9 5.0 0.1    
Rash at over           
4 years 6.6 6.5 –0.1    
Rash cleared in    
last 12 months 11.1 11.3 0.1    
Sleep disturbance 
from rash never 25.7 25.2 –0.5    
Sleep disturbance 
from rash <1 
night per week 4.8 4.8 0.0    
Sleep disturbance 
from rash >1 
night per week 1.7 1.7 0.0    
Eczema ever 17.8 20.0 2.2    
Current eczema 
symptoms 10.1 10.4 0.3    
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